ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 18, 2021 15:28 JST
Source:
Eisai
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.
The "Most Liked!" IR Award has been newly created for commemorating the 25th anniversary of the Best IR Award in 2020. The award is designed to reflect the viewpoints of companies that applied for the IR Award based on their voting, share their proactive IR experiences, and realize best practices. The theme for 2021 is "IR activities contributing sustainability," awarding companies that have actively promoted information disclosure and their dialogue with investors on sustainability-related matters. Of the companies that applied for the 2021 IR Award, 178 companies entered the 'Most Liked!" IR Award and the top 17 companies, including Eisai, were selected based on a mutual vote by the candidate companies.
For further details, please visit the JIRA website:
https://www.jira.or.jp/english/
.
Eisai has focused on disseminating information regarding financial capital and non-financial capital value relevance that link to corporate value for longer-term as well as continuously through publicizing the results of the analysis of the correlation between ESG-related indicators and PBR (Price Book-value Ratio) , holding discussion meetings with investors, or publishing the Eisai Value Creation Report. The award was given to Eisai with "empathy" for Eisai's efforts to visualize ESG.
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MUFG Bank and JCB Sign MOU for Comprehensive Strategic Alliance in ASEAN
Jul 06, 2026 13:30 JST
MHI Receives Order from Taiwan High Speed Rail Corporation for Maintenance Tools and Equipment for Yanchao Main Workshop
Jul 03, 2026 00:22 JST
Hitachi Rail completes acquisition of Clever Devices, expanding its portfolio of multi-modal transport solutions
Jul 02, 2026 23:15 JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
Jul 02, 2026 22:45 JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Jul 02, 2026 22:01 JST
Fujitsu Group achieves gold medal in EcoVadis sustainability rating
Jul 02, 2026 15:00 JST
NEC drives digital transformation at Messer Gases in Brazil with Cisco advanced networking and security solutions
Jul 02, 2026 15:00 JST
JCB Contactless Payment Now Available on Taipei Metro
Jul 01, 2026 10:00 JST
Hitachi High-Tech opens Innovation Center Eindhoven in the Netherlands to accelerate open innovation
Jul 01, 2026 00:59 JST
Honda to Commemorate 40th Anniversary of Its First F1(TM) Title
Jul 01, 2026 00:48 JST
Honda Issues "Honda ESG Report 2026"
Jul 01, 2026 00:24 JST
Sharp Signs Memorandum of Understanding with Major Global Satellite Operator SES to Build a Collaboration in Satellite Communication Services
Jul 01, 2026 00:09 JST
Mitsubishi Motors to Bring Authentic Off-Road Performance to Life with its All-New Pajero Cross-Country SUV
Jun 30, 2026 23:46 JST
MHIEC Completes Rebuild of Nagasaki City East Plant
Jun 30, 2026 23:04 JST
NEC Recognized as a Specialist in Gartner(R) Emerging Market Quadrant for Physical AI Services - Established Vendors
Jun 30, 2026 22:47 JST
DENSO and TUV Rheinland Japan Confirm the Practicality of Battery Passport for AESC's Energy Storage Product Using Actual Data
Jun 30, 2026 22:10 JST
Mitsubishi Shipbuilding Receives Order for the MAmmoSS(R) Ammonia Fuel Handling System
Jun 27, 2026 13:16 JST
MHI Study Results Indicate Potential Cost Reductions in the Decarbonization Value Chain Using Green Hydrogen and Ammonia Produced in India
Jun 27, 2026 13:00 JST
Foxconn and Sharp Signs Memorandum of Understanding for Strategic Collaboration in New Business Areas
Jun 27, 2026 12:44 JST
DENSO Group Formulates New Environmental Policy "Eco Vision 2035"
Jun 27, 2026 11:58 JST
More Latest Release >>
Related Release
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
7/2/2026 10:45:00 PM JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
7/2/2026 10:01:00 PM JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
6/17/2026 1:28:00 PM JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
More Press release >>